Irodalomjegyzék
1 Nam SY, Choi IJ, Ryu KH, Park BJ, Kim HB, Nam BH. Abdominal visceral adipose tissue volume is
associated with increased risk of erosive esophagitis in men and women. Gastroenterology. 2010
Dec;139(6):1902-1911.
2 Pandeya N, Webb PM, Sadeghi S, Green AC, Whiteman DC; Australian Cancer Study. Gastrooesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by
smoking, NSAIDs or acid suppressants? Gut. 2010 Jan;59(1):31-38.
3 Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on
the risk of Barrett’s esophagus. Am J Gastroenterol. 2010 Aug;105(8):1730-1737.
4 de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of
malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut.
2010 Aug;59(8):1030-1036.
73
5 Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent
RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HG, Meijer GA, Bergman JJ. Lowgrade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010
Jul;105(7):1523-1530.
6 Fass R, Ofman JJ. Gastroesophageal reflux disease–should we adopt a new conceptual framework?
Am J Gastroenterol. 2002 Aug;97(8):1901-9.
7 Huo X, Zhang HY, Zhang XI, Lynch JP, Strauch ED, Wang JY, Melton SD, Genta RM, Wang DH,
Spechler SJ, Souza RF. Acid and bile salt-induced CDX2 expression differs in esophageal squamous
cells from patients with and without Barrett’s esophagus. Gastroenterology. 2010 Jul;139(1):194-203.
8 Nam SY, Choi IJ, Ryu KH, Kim BC, Kim CG, Nam BH. Effect of Helicobacter pylori infection and
its eradication on reflux esophagitis and reflux symptoms. Am J Gastroenterol. 2010
Oct;105(10):2153-2162.
9 Farré R, Fornari F, Blondeau K, Vieth M, De Vos R, Bisschops R, Mertens V, Pauwels A, Tack J,
Sifrim D. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal
non-exposed human oesophagus. Gut. 2010 Feb;59(2):164-169.
10 Savarino E, Tutuian R, Zentilin P, Dulbecco P, Pohl D, Marabotto E, Parodi A, Sammito G,
Gemignani L, Bodini G, Savarino V. Characteristics of reflux episodes and symptom association in
patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH
off therapy. Am J Gastroenterol. 2010 May;105(5):1053-1061.
11 Beaumont H, Bennink RJ, de Jong J, Boeckxstaens GE. The position of the acid pocket as a major
risk factor for acidic reflux in healthy subjects and patients with GORD. Gut. 2010 Apr;59(4):441-
451.
12 Young RL, Page AJ, Cooper NJ, Frisby CL, Blackshaw LA. Sensory and motor innervation of the
crural diaphragm by the vagus nerves. Gastroenterology. 2010 Mar;138(3): 1091-1101.
13 Poh CH, Gasiorowska A, Allen L, Navarro-Rodriguez T, Mizyed I, Powers J, Moty B, Quan SF,
Willis MR, Ashpole N, Malagon I, Fass R. Reassessment of the principal characteristics of
gastroesophageal reflux during the recumbent period using integrated actigraphy-acquired
information. Am J Gastroenterol. 2010 May;105(5): 1024-1031., Allen L, Poh CH, Gasiorowska A,
Malagon I, Navarro-Rodriguez T, Cui H, Powers J, Moty B, Willis MR, Ashpole N, Quan SF, Fass R.
Increased oesophageal acid exposure at the beginning of the recumbent period is primarily a
recumbent-awake phenomenon. Aliment Pharmacol Ther. 2010 Sep;32(6):787-794.
14 McElholm AR, McKnight AJ, Patterson CC, Johnston BT, Hardie LJ, Murray LJ; Finbar Group. A
population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia,
adenocarcinoma sequence. Gastroenterology. 2010 Jul;139 (1):204-212.
15 Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, Lambeth D, Souza RF, Spechler SJ,
Cao W. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma.
Gut. 2010 Feb;59(2):170-180., Hong J, Behar J, Wands J, Resnick M, Wang LJ, Delellis RA, Lambeth
D, Cao W. Bile acid reflux contributes to development of esophageal adenocarcinoma via activation
of phosphatidylinositol-specific phospholipase Cgamma2 and NADPH oxidase NOX5-S. Cancer Res.
2010 Feb 1;70(3):1247-1255., Hong J, Resnick M, Behar J, Wang LJ, Wands J, DeLellis RA, Souza
RF, Spechler SJ, Cao W. Acid-induced p16 hypermethylation contributes to development of
esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol Gastrointest
Liver Physiol. 2010 Sep;299(3):G697-706.
74
16 Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, Montgomery GW, Green AC,
Hayward NK, Webb PM; Australian Cancer Study. Association of Helicobacter pylori infection with
reduced risk for esophageal cancer is independent of environmental and genetic modifiers.
Gastroenterology. 2010 Jul;139(1): 73-83.
17 Dent J, Vakil N, Jones R, Bytzer P, Schöning U, Halling K, Junghard O, Lind T. Accuracy of the
diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the
Diamond Study. Gut. 2010 Jun;59(6):714-721.
18 Wang FW, Tu MS, Chuang HY, Yu HC, Cheng LC, Hsu PI. Erosive esophagitis in asymptomatic
subjects: risk factors. Dig Dis Sci. 2010 May;55(5):1320-1324.
19 Gonzalez S, Yu WM, Smith MS, Slack KN, Rotterdam H, Abrams JA, Lightdale CJ. Randomized
comparison of 3 different-sized biopsy forceps for quality of sampling in Barrett’s esophagus.
Gastrointest Endosc. 2010 Nov;72(5): 935-940.
20 Kumaravel A, Lopez R, Brainard J, Falk GW. Brush cytology vs. endoscopic biopsy for the
surveillance of Barrett’s esophagus. Endoscopy. 2010 Oct;42(10):800-805.
21 Pohl J, Pech O, May A, Manner H, Fissler-Eckhoff A, Ell C. Incidence of macroscopically occult
neoplasias in Barrett’s esophagus: are random biopsies dispensable in the era of advanced
endoscopic imaging? Am J Gastroenterol. 2010 Nov;105(11):2350-6.
22 Zheng L, Tong Q, Weng M, He J, Lv Q, Wu Z, Du Z, Mei H, Hou X. Expression of resistin-like
molecule beta in Barrett’s esophagus: a novel biomarker for metaplastic epithelium. Dig Dis Sci. 2010
Jan;55(1):32-9.
23 Fu YY, Tang SC. At the movies: 3-dimensional technology and gastrointestinal histology.
Gastroenterology. 2010 Oct; 139(4): 1100-1105.
24 Curvers WL, Herrero LA, Wallace MB, Wong Kee Song LM, Ragunath K, Wolfsen HC, Prasad GA,
Wang KK, Subramanian V, Weusten BL, Ten Kate FJ, Bergman JJ. Endoscopic tri-modal imaging is
more effective than standard endoscopy in identifying early-stage neoplasia in Barrett’s esophagus.
Gastroenterology. 2010 Oct;139(4):1106-1114.
25 Bajbouj M, Vieth M, Rösch T, Miehlke S, Becker V, Anders M, Pohl H, Madisch A, Schuster T,
Schmid RM, Meining A. Probe-based confocal laser endomicroscopy compared with standard fourquadrant biopsy for evaluation of neoplasia in Barrett’s esophagus. Endoscopy. 2010 Jun;42(6):435-
40.
26 Neumann H, Kiesslich R, Wallace MB, Neurath MF. Confocal laser endomicroscopy: technical
advances and clinical applications. Gastroenterology. 2010 Aug;139(2):388-392,
27 Li M, Anastassiades CP, Joshi B, Komarck CM, Piraka C, Elmunzer BJ, Turgeon DK, Johnson TD,
Appelman H, Beer DG, Wang TD. Affinity peptide for targeted detection of dysplasia in Barrett’s
esophagus. Gastroenterology. 2010 Nov;139(5):1472-1480.
28 Keller J, Fibbe C, Volke F, Gerber J, Mosse AC, Reimann-Zawadzki M, Rabinovitz E, Layer P,
Swain P. Remote magnetic control of a wireless capsule endoscope in the esophagus is safe and
feasible: results of a randomized, clinical trial in healthy volunteers. Gastrointest Endosc. 2010
Nov;72(5):941-6.
75
29 Heresbach D, Leray E, d’Halluin PN, Cholet F, Lapalus MG, Gaudric M, Ben Soussan E, Gaudin
JL, Vahedi K, Quentin V, Filoche B, Saurin JC, Chaussade S, Ponchon T.
Diagnostic accuracy of esophageal capsule endoscopy versus conventional upper digestive endoscopy
for suspected esophageal squamous cell carcinoma.
Endoscopy. 2010 Feb;42(2):93-97.
30 Pech O, Günter E, Dusemund F, Origer J, Lorenz D, Ell C. Accuracy of endoscopic ultrasound in
preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer.
Endoscopy. 2010 Jun;42(6):456-461.
31 Pech O, Günter E, Dusemund F, Ell C. Value of high-frequency miniprobes and conventional
radial endoscopic ultrasound in the staging of early Barrett’s carcinoma. Endoscopy. 2010
Feb;42(2):98-103.
32 Moss A, Bourke MJ, Hourigan LF, Gupta S, Williams SJ, Tran K, Swan MP, Hopper AD, Kwan V,
Bailey AA. Endoscopic resection for Barrett’s high-grade dysplasia and early esophageal
adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J
Gastroenterol. 2010 Jun;105(6):1276-83.
33 Samadi F, Levine MS, Rubesin SE, Katzka DA, Laufer I: Feline Esophagus and Gastroesophageal
Reflux. AJR 2010; 194:972-976
34 Pennathur A., Awais O., Luketich J. D.: Minimally Invasive Esophagectomy for Barrett’s with
High-grade Dysplasia and Early Adenocarcinoma of the Esophagus. J Gastrointest Surg 2010,
14:948-950.
35 Vasiliadis KV, Viazis N, Vlachogiannakos J, Sgouros SN, Stefanidis G, Archimandritis A,
Karamanolis DG. Efficacy of three different dosages of esomeprazole in the long-term management of
reflux disease: a prospective, randomized study, using the wireless Bravo pH system. Am J
Gastroenterol. 2010 Feb; 105(2): 308-313.
36 Vaezi MF, Hagaman DD, Slaughter JC, Tanner SB, Duncavage JA, Allocco CT, Sparkman C,
Clement LE, Wasden CM, Wirth D, Goutte M, McCafferty BA, Lanza DC. Proton pump inhibitor
therapy improves symptoms in postnasal drainage. Gastroenterology. 2010 Dec;139(6):1887-1893.
37 ( Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial
overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010 Jun;8(6):504-8.
38 ( Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung HC, Song IS. Proton pump inhibitors
as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol.
2010 Jul 28;16(28):3573-3577.
39 Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor
antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010
Jul;139(1):93-101., Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not
associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010 Mar;
138(3): 896-904.
40 van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and
gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch
cohort study. Am J Gastroenterol. 2010 Nov;105(11):2430-2436
76
41 O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD,
Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic
effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an
analysis of two randomised trials Lancet. 2009 Sep 19;374(9694):989-997.
42 Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P,
Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP; COGENT Investigators. Clopidogrel
with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11;363(20):1909-
1917.
43 Chen WY, Chang WL, Tsai YC, Cheng HC, Lu CC, Sheu BS. Double-dosed pantoprazole
accelerates the sustained symptomatic response in overweight and obese patients with reflux
esophagitis in Los Angeles grades A and B. Am J Gastroenterol. 2010 May;105(5):1046-52.)
44 Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth
defects. N Engl J Med. 2010 Nov 25;363(22):2114-2123.
45 Fiocca R, Mastracci L, Engström C, Attwood S, Ell C, Galmiche JP, Hatlebakk J, Junghard O,
Lind T, Lundell L; LOTUS trial collaborators. Long-term outcome of microscopic esophagitis in
chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS
trial. Am J Gastroenterol. 2010 May;105(5): 1015-1023.
46 Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J, Silberg DG, Sifrim D.
Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with
gastroesophageal reflux disease. Gastroenterology. 2010 Aug;139(2):409-17.
47 Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux
disease. Gerson LB, Huff FJ, Hila A, Hirota WK, Reilley S, Agrawal A, Lal R, Luo W, Castell D. Am J
Gastroenterol. 2010 Jun;105(6):1266-1275.
48 Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors)
and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology.
2010 Jun;138(7):2260-2266.
49 Nguyen DM, Schwartz J, Richardson P, El-Serag HB. Oral bisphosphonate prescriptions and the
risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Dig Dis Sci. 2010
Dec;55(12):3404-3407.
50 Fleischer DE, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, Chang KJ,
Muthasamy R, Lightdale CJ, Santiago N, Pleskow DK, Dean PJ, Wang KK. Endoscopic
radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter
trial. Endoscopy. 2010 Oct;42(10):781-789.
51 Lagergren J, Ye W, Lagergren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux
surgery. Gastroenterology. 2010 Apr;138(4): 1297-1301.
52 Braghetto I., Korn O., Csendes A., Burdiles P., Valladares H., Brunet L.: Postoperative Results
After Laparoscopic Approach for Treatment of Large Hiatal Hernias: Is Mesh Always Needed? Is the
Addition o fan Antireflux Procedure Necessary? Int Surg 2010, 95:80-87.
53 Furnée E. J. B., Draaisma W. A., Gooszen H. G., Hazebroek E. J., Smout A. J. P. M., Broeders I. A.
M. J.: Tailored or Routine Addition o fan Antireflux Fundoplication in Laparoscopic Large Hiatal
Hernia Repair: A Comparative Cohort Study. World J Surg 2011, 35(1):78-84.
77
54 Luketich J. D., Nason K. S., Christie N. A., Pennathur A., Jobe B. A., Landreneau R. J., Schuchert
M. J.: Outcomes after a decade of laparoscopic giant paraesophageal hernia repair. J Thorac
Cardiovasc Surg 2010, 139:395-404.
55 Frantzides C. T., Carlson M. A., Loizides S., Papafili A., Luu M., Roberts J., Zeni T., Frantzides A.:
Hiatal hernia repair with mesh: a survey of SAGES members. Surg Endosc 2010, 24:1017-1024.
56 Hoppo T., Immanuel A., Schuchert M., Dubrava Z., Smith A., Nottle P., Watson D. I., Jobe B. A.:
Transoral Incisionless Fundoplication 2.0 Procedure Using EsophyXTM for Gastroesophageal Reflux
Disease. J Gastrointest Surg 2010, 14:1895-1901
57 Velanovich V.: Endoscopic, endoluminal fundoplication for gastroesophageal reflux disease:
Initial experience and lessons learned. Surgery 2010, 148:646-653.
58 Zehetner J., Lipham J. C., Ayazi S., Oezcelik A., Abate E., Chen W., DeMeester S. R., Sohn H. J.,
Banki F., Hagen J. A., Dickey M., DeMeester T. R.: A simplified technique for intrathoracic stomach
repair: laparoscopic fundoplication with Vicryl mesh and BioGlue crural reinforcement. Surg Endosc
2010, 24:675-679.
59 Hamzaoglu I., Karahasanoglu T., Aytac E., Karatas A., Baca B.: Transumbilical Totally
Laparoscopic Single-Port Nissen Fundoplication: A New Method of Liver Retraction: The Istanbul
Technique. J Gastrointest Surg 2010, 14:1035-1039.
60 Tsimogiannis K. E., Pappas-Gogos G. K., Benetatos N., Tsironis D., Farantos C., Tsimoyiannis E.
C.: Laparoscopic Nissen fundoplication combined with posterior gastropexy in surgical treatment of
GERD. Surg Endosc 2010, 24:1303-1309.
61 Broeders J. A., Draaisma W. A., Bredenoord A. j., Smout A. J., Broeders I. A., gooszen H. G.:
Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux
disease. Br J Surg 2010, 97(6):845-852.
62 Zingg U., Smith L., Carney N., Watson D. I., Jamieson G. G.: The Influence on Outcome of
Indications for Antireflux Surgery. World J Surg 2010, 34:2813-2820.
63 Tsunoda S., Jamieson G. G., Devitt P. G., Watson D. I., Thompson S. K.: Early Reoperation After
Laparoscopic Fundoplication: The Importance of Routine Postoperative Contrast Studies. World J
Surg 2010, 34:79-84.
64 Chang A. C., Lee J. S., Sawicki K. T., Pickens A., Orringer M. B.: Outcomes After Esophagectomy
in Patients With Prior Antireflux or Hiatal Hernia Surgery. Ann Thorac Surg 2010, 89:1015-1023.
65 Koch O. O., Asche K. U., Berger J., Weber E., Granderath F. A., Pointner R.: Influence of the size
of the hiatus on the rate of reherniation after laparoscopic fundoplication and refundoplication with
mesh hiatoplasty. Surg Endosc 2010, DOI 10.1007/s00464-010-1308-3.
66 Bakken JC, Wong Kee Song LM, de Groen PC, Baron TH. Use of a fully covered self-expandable
metal stent for the treatment of benign esophageal diseases. Gastrointest Endosc. 2010 Oct;72(4):712-
20.
67 Oh YS, Kochman ML, Ahmad NA, Ginsberg GG. Clinical outcomes after self-expanding plastic
stent placement for refractory benign esophageal strictures. Dig Dis Sci. 2010 May;55(5):1344-1348.
78
68 van Heel NC, Haringsma J, Spaander MC, Bruno MJ, Kuipers EJ. Short-term esophageal stenting
in the management of benign perforations. Am J Gastroenterol. 2010 Jul;105(7): 1515-1520.
69 Repici A, Vleggaar FP, Hassan C, van Boeckel PG, Romeo F, Pagano N, Malesci A, Siersema PD.
Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST
(Biodegradable Esophageal Stent) study. Gastrointest Endosc. 2010 Nov;72(5):927-934.
70 Keeling W. B., Miller D. L., Lam G. T., Kilgo P., Miller J. I., Mansour K. A., Force S. D.: Low
Mortality After Treatment for Esophageal Perforation: A Single-Center Experience. Ann Thorac Surg
2010, 90:1669-1673.
71 Schmidt S. C., Strauch S., Rösch T., Veltzke-Schlieker W., Jonas S., Pratschke J., Weidemann H.,
Neuhaus P., Schumacher G.: Management of esophageal perforations. Surg Endosc 2010, 24:2809-
2813.
72 Shaker H., Elsayed H., Whittle I., Hussein S., Shackcloth M.: The influence of the „golden 24-h
rule” on the prognosis of oesophageal perforation in the modern era. European Journal of Cardiothoracic Surgery 2010, 216-222.
73 Loske G., Schorsch T., Müller C.: Endoscopic vacuum sponge therapy for esophageal defects. Surg
Endosc 2010, 24:2531-2535.
74 Sadowski DC, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A
population-based study. Neurogastroenterol Motil. 2010 Sep;22(9):e256-261.
75 Leeuwenburgh I, Scholten P, Alderliesten J, Tilanus HW, Looman CW, Steijerberg EW, Kuipers
EJ. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J
Gastroenterol. 2010 Oct;105(10):2144-2149.
76 Kraichely RE, Farrugia G, Pittock SJ, Castell DO, Lennon VA. Neural autoantibody profile of
primary achalasia. Dig Dis Sci. 2010 Feb;55(2):307-311.
77 Hong SJ, Bhargava V, Jiang Y, Denboer D, Mittal RK. A unique esophageal motor pattern that
involves longitudinal muscles is responsible for emptying in achalasia esophagus. Gastroenterology.
2010 Jul;139(1):102-111.
78 Sinan H, Tatum RP, Soares RV, Martin AV, Pellegrini CA, Oelschlager BK. Prevalence of
respiratory symptoms in patients with achalasia. Dis Esophagus. 2010 Nov 12. [Epub ahead of print]
79 Alderliesten J, Conchillo JM, Leeuwenburgh I, Steyerberg EW, Kuipers EJ. Predictors for outcome
of failure of balloon dilatation in patients with achalasia. Gut. 2010 Nov 10. [Epub ahead of print]
80 Salvador R, Costantini M, Zaninotto G, Morbin T, Rizzetto C, Zanatta L, Ceolin M, Finotti E,
Nicoletti L, Da Dalt G, Cavallin F, Ancona E. The preoperative manometric pattern predicts the
outcome of surgical treatment for esophageal achalasia. J Gastrointest Surg. 2010 Nov;14(11):1635-
1645.
81 Porter RF, Gyawali CP. Botulinum toxin injection in dysphagia syndromes with preserved
esophageal peristalsis and incomplete lower esophageal sphincter relaxation. Neurogastroenterol
Motil. 2010 Oct 1. [Epub ahead of print]
82 Li YD, Tang GY, Cheng YS, Chen NW, Chen WX, Zhao JG. 13-year follow-up of a prospective
comparison of the long-term clinical efficacy of temporary self-expanding metallic stents and
pneumatic dilatation for the treatment of achalasia in 120 patients. AJR Am J Roentgenol. 2010
79
Dec;195(6):1429-1437., Li YD, Cheng YS, Li MH, Chen NW, Chen WX, Zhao JG. Temporary selfexpanding metallic stents and pneumatic dilation for the treatment of achalasia: a prospective study
with a long-term follow-up. Dis Esophagus. 2010 Jul;23(5):361-367., Cheng YS, Ma F, Li YD, Chen
NW, Chen WX, Zhao JG, Wu CG. Temporary self-expanding metallic stents for achalasia: a
prospective study with a long-term follow-up. World J Gastroenterol. 2010 Oct 28;16(40):5111-5117.
83 Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo
S. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy. 2010 Apr;42(4):265-
271.
84 Perretta S, Dallemagne B, Allemann P, Marescaux J. Multimedia manuscript. Heller myotomy and
intraluminal fundoplication: a NOTES technique. Surg Endosc. 2010 Nov;24(11):2903.
85 Reynoso J. F., Tiwari M. M., Tsang A. W., Oleynikov D.: Does illness severity matter? A
comparison of laparoscopic esophagomyotomy with fundoplication and esophageal dilation for
achalasia. Surg Endosc DOI 10.1007/s00464-010-1415-1
86 Patti M. G., Herbella F. A.: Fundoplication After Laparoscopic Heller Myotomy for Esophageal
Achalasia: What Type? J Gastrointest Surg 2010, 14:1453-1458.
87 Khandelwal S., Petersen R., Tatum R., Sinan H., Aaronson D., Mier F., Martin A. V., Pellegrini C.
A., Oelschlager B. K.: Improvement of Respiratory Symptoms Following Heller Myotomy for
Achalasia. J Gastrointest Surg DOI 10.1007/s11605-1397-2.
88 Mattioli S., Ruffato A., Lugaresi M., Pilotti V., Aramini B., D’Ovidio F.: Long-term results of the
Heller-Dor operation with intraoperative manometry for the treatment of esophageal achalasia. J
Thorac Cardiovasc Surg 2010, 140(5):962-969.
89Chen T, Yang Z, Li X, Wang Q, Qian L, Wang R: Evaluation of entire gastric fundic and esophageal
varices secondary to posthepatitic cirrhosis: portal venography using 64-row MDCT. Abdom Imaging
2010;35:1-7
90 Du L., Wu W., Zhang Y., Sun Z., Hu H., Liu X., Liu Q.: Effects of modified splenocaval shunt plus
devascularization on esophagogastric variceal bleeding: a comparative study of this treatment and
devascularization only in cirrhotic portal hypertension. J Hepatobiliary Pancreat Sci 2010,
17(5):657-665.
91 Oida T., Mimatsu K., Kano H., Kawasaki A., Kuboi Y., Fukino N., Amano S.: Post-gastrectomy
spleen enlargement and esophageal varices: distal vs total gastrectomy. World J Gastroenteol 2010,
16(22):2801-2805.
92 Foroutan M, Norouzi A, Molaei M, Mirbagheri SA, Irvani S, Sadeghi A, Derakhshan F, Tavassoli
S, Besharat S, Zali M. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux
disease. Dig Dis Sci. 2010 Jan;55(1):28-31.
93 Vicario M, Blanchard C, Stringer KF, Collins MH, Mingler MK, Ahrens A, Putnam PE, Abonia JP,
Santos J, Rothenberg ME. Local B cells and IgE production in the oesophageal mucosa in
eosinophilic oesophagitis. Gut. 2010 Jan;59(1):12-20.
94 Hejazi RA, Reddymasu SC, Sostarich S, McCallum RW. Disturbances of esophageal motility in
eosinophilic esophagitis: a case series. Dysphagia. 2010 Sep;25(3):231-237.
95 White SB, Levine MS, Rubesin SE, Spencer GS, Katzka DA, Laufer I: The Small-Caliber
Esophagus: Radiographic Sign of Idiopathic Eosinophilic Esophagitis. Radiology 2010;256:127-134
80
96 Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children
with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology. 2010
Aug;139(2):418-429.
97 Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, Bussmann C, Beglinger C,
Schoepfer A, Simon HU. Budesonide is effective in adolescent and adult patients with active
eosinophilic esophagitis. Gastroenterology. 2010 Nov;139(5):1526-1537.
98 Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel
J, Byrne M, Simon HU. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic
oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010 Jan;59(1):21-30.
99 Schoepfer AM, Gonsalves N, Bussmann C, Conus S, Simon HU, Straumann A, Hirano I.
Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying
inflammation. Am J Gastroenterol. 2010 May;105(5):1062-1070.
100 Xiao YL, Peng S, Tao J, Wang AJ, Lin JK, Hu PJ, Chen MH. Prevalence and symptom pattern of
pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria.
Am J Gastroenterol. 2010 Dec;105(12):2626-2631.
101 Lee H, Kim JH, Min BH, Lee JH, Son HJ, Kim JJ, Rhee JC, Suh YJ, Kim S, Rhee PL. Efficacy of
venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized,
double-blind, placebo-controlled, crossover trial. Am J Gastroenterol. 2010 Jul;105(7):1504-1512.
102 Choi S. H., Kim Y. T., Han K. N., Ra Y. J., Kang C. H., Sung S. W., Kim J. H.: Surgical
management of the esophageal leiomyoma: lessons from a retrospective review. Dis Esophagus 2010,
DOI: 10.1111/j.1442-2050.2010.01144.x.
103 Wang Q., Ye T., Jiang W., Lin ZW.: Video-assisted thoracoscopic surgery int he treatment of
esophageal leiomyoma: a report of 39 cases. Zhonghua Wei Chang Wai Ke Za Zhi 2010, 13(2):145-
147.
104 Koike Y., Obana T., Fujita N., Hirasawa D., Suzuki T., Sugawara T., Ohira T., Harada Y., Maeda
Y., Suzuki K., Yamagata T., Noda Y., Oikawa M., Sawai T.: A case of giant esophageal leiomyoma
successfully resected by endoscopic submucosal dissection followed by retrieval via laparotomy.
Nippon Shokakibyo Gakkai Zasshi 2010, 107(11):1780-1785.
105 Umeoka Sh, Koyama T, Watanabe G, Saga Ts, Kataoka M, Togashi K, Hatabu H: Preoperative
Local Staging of Esophageal Carcinoma Using Dual-Phase Contrast-Enhanced Imaging With MultiDetector Row Computed Tomography: Value of the Arterial Phase Images. J Comput Assist Tomogr
2010;34:406-412
106 Kato T, Takase K, Ichikawa H, Satomi S, Takahashi Sh: Demonstration of the Anatomy of the
Esophageal Artery Using Multidetector-Row Helical Computed Tomography. J Comput Assist
Tomogr 2010;34:939-944
107 Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV: Additional benefit of 18Ffluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of
oesophageal cancer. Eur Radiol Online First, 7 September 2010
108 Kaida H, Ishibashi M, Yuzuriha M, Kurata S, Arikawa S, Kawahara A, Uozumi J, Uchida M,
Kobayashi M, Hirose Y, Fujita H, Kage M, Hayabuchi N: Glucose Transporter Expression of an
Esophageal Gastrointestinal Tumor Detected by F-18 FDG PET/CT. Clin Nucl Med 2010;35:505-509
81
109 Gheysens O, Baete K, Deroose Ch M, Mottaghy F M: Paramediastinal Inflammatory Changes
After Chemoradiation Detected on FDG PET-CT Imaging. Clin Nucl Med 2010;35:355-356
110 Knox J. J., Wong R., Visbal A. L., Horgan A. M., Guindi M., Hornby J., Xu W., Ringash J.,
Keshavjee S., Chen E., Haider M., Darling G.: Phase 2 Trial of Preoperative Irinotecan Plus
Cisplatin and Conformal Radiotherapy, followed by Surgery for Esophageal Cancer. Cancer 2010,
116:4023-4032.
111 Takeuchi H., Saikawa Y., Oyama T., Ozawa S., Suda K., Wada N., Takahashi T., Nakamura R.,
Shigematsu N., Ando N., Kitajima M., Kitagawa Y.: Factors Influencing the Long-Term Survival in
Patients with Esophageal Cancer Who Underwent Esophagectomy After Chemoradiotherapy. World J
Surg 2010, 34:277-284.
112 Vallböhmer D., Hölscher A. H., DeMeester S., DeMeester T., Salo J. Peters J., Lerut T., Swisher
S. G., Schröder W., Bollschweiler E., Hofstetter W.: A multicenter study of survival after neoadjuvant
radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 2010,
252(5):744-749.
113 DeMeester S. R.: Evaluation and Treatment of Superficial Esophageal Cancer. J Gastrointest
Surg 2010, 14(Suppl 1):S94-S100.
114 DeMeester S. R.: Vagal-Sparing Esophagectomy: Is It a Useful Addition? Ann Thorac Surg 2010,
89:S2156-2158.
115 Kranzfelder M., Büchler P., Lange K., Friess H.: Treatment Options for Squamous Cell Cancer of
the Esophagus: A Systematic Review of the Literature. J Am Coll Surg 2010, 210(3):351-359.
116 Rizk N. P., Ishwaran H., Rice T. W., Chen L.Q., Schipper P. H., Kesler K. A., Law S., Lerut T. E.
M. R., Reed C. E., Salo J. A., Scott W. J., Hofstetter W. L., Watson T. J., Allen M. S., Rusch V. W.,
Blackstone E. H.: Optimum Lymphadenectomy for Esophageal Cancer. Ann Surg 2010, 251:46-50.
117 Puntambekar S. P., Agarwal G. A., Joshi S. N., Rayate N. V., Sathe R. M. Patil A. M.:
Thoracolaparoscopy int he lateral position for esophageal cancer: the experience of a single
institution with 112 consecutive patients. Surg Endosc 2010, 24:2407-2414.
118 Dai J. G., Zhang Z. Y., Min J. X., Huang X. B., Wang J. S.: Wrapping of the omental pedicle flap
around esophagogastric anastomosis after esophagectomy for esophageal cancer. Surgery 2010,
119 Schuchert M. J., Abbas G., Nason K. S., Pennathur A., Awais O., Santana M., Pereira R., Oostdyk
A., Luketich J. D., Landreneau J.: Impact of anastomotic leak on outcomes after transhiatal
esophagectomy. Surgery 2010, 148:831-840.
120 Mohammad A. B. Zahoor A. N., Tufail A. D., Riyaz A. L., Abdul M. D.: role of intraoperative
sentinel lymph node mapping int he management of carcinoma of the esophagus. Saudi J
Gastroenterol 2010, 16(3):168-173.
121 Eroglu A., Turkyilmaz A., Subasi M., Karaoglanoglu N.: The use of self-expandable metallic
stents for palliative treatment of inoperable esophageal cancer. Dis Esophagus 2010, 23(1):64-70.
122 Stahl M., Chemoradiotherapy plus surgery
Annals of Oncology Volume 21, Suppl. 6. 2010.
123 Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG,
Schröder W, Bollschweiler E, Hofstetter W. A multicenter study of survival after neoadjuvant
82
radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010
Nov;252(5):744-9.
124 Okines A, Sharma B, Cunningham D, Perioperative management of esophageal cancer.
Nat Rev Clin Oncol. 2010 Apr;7(4):231-8. Epub 2010 Mar 9.
125 Malthaner R.,Wong RK, Spithoff K., Gastrointestinal Cancer Disease Site Group of Cancer Care
Ontario’s Program in Evidence-based Care. Preoperative or postoperative therapy for resectable
oesophageal cancer: an updated practice guideline.
Clin Oncol (R Coll Radiol). 2010 May;22(4):250-6.
126 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer.
World J Gastroenterol. 2010 Aug 14;16(30):3793-803.
127 Ku GY, Ilson DH. Esophagogastric cancer: targeted agents.
Cancer Treat Rev. 2010 May;36(3):235-48. Epub 2010 Feb 1.
128 Gros SJ, Kurschat N, Dohrmann T, Reichelt U, Dancau AM, Peldschus K, Adam G, Hoffman RM,
Izbicki JR, Kaifi JT. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly
metastatic orthotopic model of esophageal carcinoma.
Mol Cancer Ther. 2010 Jul;9(7):2037-45. Epub 2010 Jul 6.
129 Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J,
Hejna M, Birner P. Expression of Her-2 in carcinomas of the esophagus.
Am J Surg Pathol. 2010 Dec;34(12):1868-73.
130 Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A
phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the
esophagus.
Cancer. 2010 Nov 8. [Epub ahead of print]
131 Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL, Hawkins RE, Thistlethwaite FC.
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in
advanced gastric and esophageal adenocarcinoma.
Clin Cancer Res. 2010 Mar 1;16(5):1662-72. Epub 2010 Feb 23.
132 Ekman S, Bergqvist M, Tell R, Bergström S, Lennartsson J. Hsp90 as a therapeutic target in
patients with oesophageal carcinoma.
Expert Opin Ther Targets. 2010 Mar;14(3):317-28.
133 Schauer M, Knoefel WT. Neoadjuvant chemotherapy in Barrett’s carcinoma – prognosis and
response prediction. Anticancer Res. 2010 Apr;30(4):1065-70.
134 Schauer M, Janssen KP, Rimkus C, Raggi M, Feith M, Friess H, Theisen J. Microarray-based
response prediction in esophageal adenocarcinoma.
Clin Cancer Res. 2010 Jan 1;16(1):330-7. Epub 2009 Dec 22.
135 Jost C, Binek J, Schuller JC, Bauerfeind P, Metzger U, Werth B, Knuchel J, Frossard JL,
Bertschinger P, Brauchli P, Meyenberger C, Ruhstaller T. Endosonographic radial tumor thickness
after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally
advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical
Cancer Research (SAKK 75/02). Gastrointest Endosc. 2010 Jun;71(7):1114-21. Epub 2010 Mar 20.
83
136 Papp A, Cseke L, Farkas R, Pavlovics G, Horvath G, Varga G, Szigeti A, Bellyei S, Marton S,
Poto L, Kalmar K, Vereczkei A, Pozsgai E, Horvath OP. Chemo-radiotherapy in locally advanced
squamous cell oesophageal cancer–are upper third tumours more responsive? Pathol Oncol Res.
2010 Jun;16(2):193-200. Epub 2009 Sep 17.
137 Tanaka K, Yano M, Motoori M, Kishi K, Miyashiro I, Shingai T, Gotoh K, Noura S, Takahashi H,
Ohue M, Yamada T, Ohigashi H, Yamamoto T, Yamasaki T, Doki Y, Ishikawa O. CEA-antigen and
SCC-antigen mRNA expression in peripheral blood predict hematogenous recurrence after resection
in patients with esophageal cancer.
Ann Surg Oncol. 2010 Oct;17(10):2779-86. Epub 2010 Apr 22.
138 Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, Todo M, Shiozaki A, Kubota T,
Ichikawa D, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T, Otsuji E. Elevated serum CRP levels after
induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and
local tumor site in patients with advanced esophageal cancer.
.J Surg Oncol. 2011 Jan 1;103(1):62-8.
139 Conroy T, Yataghène Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel
X, Lamezec B, Rio E, Le Prisé E, Peiffert D, Adenis A Phase II randomised trial of chemoradiotherapy
with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer.
Br J Cancer. 2010 Oct 26;103(9):1349-55. Epub 2010 Oct 12.
140 Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II Study
of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic
Gastroesophageal Adenocarcinoma.
J Clin Oncol. 2010 Dec 28. [Epub ahead of print]
141 Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd,
Hainsworth JD. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with
concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Clin Oncol. 2010 May 1;28(13):2213-9. Epub 2010 Mar 29.
142 Cancer. 2010 Sep 1;116(17):4023-32.
Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by
surgery for esophageal cancer.
Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, Xu W, Ringash J, Keshavjee S, Chen
E, Haider M, Darling G.
143Inoue H., Kudo S. E.: Per-oral endoscopic myotomy (POEM) for 43 consecutive cases of
esophageal achalasia. Nippon Rinsho 2010, 68(9):1749-1752.
144 Perretta S., Dallemagne B., Allemann P., Marescaux J.: Multimedia manuscript. Heller myotomy
and intraluminal fundoplication: a NOTES technique. Surg Endosc 2010, 24(11):2904.
